Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Announces Q1 (Standalone & Consolidated) results & Limited Review Report (Standalone & Consolidated) for the Quarter ended June 30, 2016

 Cadila Healthcare Ltd has announced the following results for the quarter ended June 30, 2016:The Unaudited Standalone results for the Quarter ended June 30, 2016The Company has posted a net profit of Rs. 1651 million for the quarter ended June 30, 2016 as compared to Rs. 5650 million for the quarter ended June 30, 2015. Total Income has decreased from Rs. 19329 million for the quarter ended June 30, 2015 to Rs. 13155 million for the quarter ended June 30, 2016....
03-08-2016
Bigul

Post results conference call with investors / analysts

 Cadila Healthcare Ltd has informed BSE regarding "Post results conference call with investors / analysts".
22-07-2016
Bigul

Updates

 Cadila Healthcare Ltd has informed BSE that Company's US based 100% subsidiary company Zydus Pharmaceuticals (USA) Inc. (Zydus) will begin informing on July 12, 2016 its customers that Zydus will start selling an authorized generic of Asacol HD (mesalamine delayed - release tablets 800 mg) in the United States commencing on August 01, 2016.
14-07-2016
Bigul

Overweight Cadila Healthcare Ltd., target Rs 399 : Morgan Stanley

 Morgan Stanley estimates that Cadila can generate up to $35 million upside and could generate over 90 per cent in PBT margins
13-07-2016
Bigul

Shareholding for the Period Ended June 30, 2016

 Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here
11-07-2016
Bigul

Q1 results on August 03, 2016

 Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 03, 2016, inter alia, to consider & approve the unaudited financial results for the quarter ended on June 30, 2016 (Q1).Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window shall remain closed from July 25,...
11-07-2016
Bigul

Zydus Cadila gets USFDA nod for diabetes treatment drug

 Drug firm Zydus Cadila has received final approval from the US health regulator to market Nateglinide tablets, used for the treatment of diabetes in the American market. Zydus Cadila has received f...
11-07-2016
Bigul

Zydus receives final approval from the USFDA for Nateglinide Tablets USP

 Cadila Healthcare Ltd has informed BSE regarding a Press Release dated July 11, 2016 titled "Zydus receives final approval from the USFDA for Nateglinide Tablets USP".
11-07-2016
Bigul

Cadila eyes growth opportunity in US, LatAm formulation mkts

 During 2015-16, the company's business in the US remained the largest contributor to the consolidated revenue, which crossed $600 million in sales for the first time
10-07-2016
Bigul

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016

 Cadila Healthcare Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
09-07-2016
Next Page
Close

Let's Open Free Demat Account